top of page

NCI-2022-07859

A Phase 1b/2 Study of the PARP Inhibitor Niraparib in Combination with Trastuzumab in Patients with Metastatic HER2 Breast Cancer


This medical study is designed to evaluate the safety and efficacy of a drug combination of niraparib and trastuzumab in the treatment of metastatic HER2+ breast cancer. Niraparib is a PARP inhibitor, a type of drug that works by preventing the repair of DNA damage in cancer cells. Trastuzumab is a monoclonal antibody that targets the HER2 protein, which is overexpressed in many HER2+ breast cancers. The study is a single-arm, open-label study, meaning that all participants will receive the same treatment combination and the study will not be blinded. The study is being conducted at multiple medical centers in the United States.

HER2+ breast cancer: It is a type of breast cancer where cancer cells have higher-than-normal levels of HER-2 receptors are called HER-2 positive. These receptors are like tiny doorways on the surface of the cells. HER-2 positive breast cancers tend to grow and spread faster than other kinds, but they also respond well to certain drugs that target the HER-2 receptor.

Open-Label: Patients know which treatments are being given to them

single-arm: A study where sample of individuals with the targeted medical condition is given the experimental therapy and then followed over time to observe their response.

Metastatic: Cancer that has spread from its original location or organ to other parts of the body.

For more information about the trial, click the link below:

NCI-2022-07859

Clinical Trial Site: Einstein


To see all available clinical trials click here.



Recent Posts

See All

NCI-2020-02981

Phase 2 Trial of Voyager V1 (Vesicular Stomatitis Virus Expressing NIS and Human Interferon Beta, VV1), in Combination with Cemiplimab in patients with Hepatocellular Carcinoma, Non-Small Cell Lung Ca

NCI-2022-09871

An Open Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of the Combination of Lasofoxifene and Abemaciclib to the Combination of Fulvestrant and Abemaciclib for the Treatment of

NCI-2022-08654

A Phase 1b Open-Label Multicenter Study of OP-1250 in Combination With the CDK4/6 Inhibitor Ribociclib or With the PI3K Inhibitor Alpelisib in Adult Subjects With Advanced and/or Metastatic HR Positiv

Comments


bottom of page